更新于：2024-07-25
Azithromycin
阿奇霉素
更新于：2024-07-25
概要
基本信息
简介阿奇霉素是一种小分子药物，作用于细菌核糖体的50S亚基，通过抑制蛋白质合成来杀死细菌。它是一种广谱抗生素，可用于治疗多种细菌感染，包括肺炎、中耳炎、喉炎、皮肤感染和生殖系统感染等。阿奇霉素在治疗呼吸道感染方面特别有效，可以缩短治疗时间和减少复发率。它也被用于治疗梅毒和麻疹等疾病。这种药物于1991年首次批准上市，原研公司为辉瑞公司，现已成为临床使用最广泛的抗生素之一。 |
药物类型 小分子化药 |
别名 Azithromycin (INN)、Azithromycin Dihydrate、Azithromycin Hydrate + [26] |
作用机制 50S subunit抑制剂(50S核糖体亚基抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-11-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本) |
登录后查看首次获批时间轴
结构
分子式C38H72N2O12 |
InChIKeyMQTOSJVFKKJCRP-BICOPXKESA-N |
CAS号83905-01-5 |
关联
828
项与 阿奇霉素 相关的临床试验Platform for Adaptive Trials in Perinatal Units (Core Protocol)
Enhancing Lung Health in Kids With Structural Lung Damage and Malformations: a Randomized Controlled Trial on Azithromycin (AZI) for Airway Infection Prevention
A Pharmacokinetic-pharmacodynamic Study of Early Rickettsia Clearance in Murine Typhus or Scrub Typhus Patients Treated With Doxycycline or Azithromycin
100 项与 阿奇霉素 相关的临床结果
登录后查看更多信息
100 项与 阿奇霉素 相关的转化医学
登录后查看更多信息
100 项与 阿奇霉素 相关的专利（医药）
登录后查看更多信息
11,595
项与 阿奇霉素 相关的文献（医药）2024-06-01Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Microbiological findings in patients with community-acquired pneumonia: An analysis using the National Hospital Organization Clinical Data Archives
Article
作者: Fushimi, Kiyohide ; Yasunaga, Hideo ; Horiguchi, Hiromasa ; Tsuchiya, Asuka ; Yamana, Hayato ; Jo, Taisuke
Although large-scale administrative databases may be useful for studies of infectious diseases, conventional databases lack microbiological data. To illustrate the applicability of the National Hospital Organization Clinical Data Archives, a novel database of electronic medical records in Japan, we conducted a descriptive study of the microbiological findings in patients with community-acquired pneumonia using the database. We identified patients aged ≥18 years who were hospitalized for community-acquired bacterial pneumonia between April 2016 and March 2019. We evaluated the results of bacterial culture and antibacterial susceptibility of specimens obtained on the first day of hospitalization, in addition to patient characteristics, diagnosis codes, and intravenous antibiotics administered. The analysis identified 2200 eligible patients from 15 hospitals. Sulbactam-ampicillin was the most frequently used initial antibiotic (32 %), followed by ceftriaxone (22 %) and tazobactam-piperacillin (19 %). Overall, 56 %, 95 %, 56 %, and 73 % of patients with pathogen-specific diagnosis codes in the database for Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa, respectively, also tested positive for the corresponding pathogen in their sputum or blood cultures. Antibacterial susceptibilities were consistent with a previous report from Japan; 81 % of S. pneumoniae cases were resistant to azithromycin, and 48 % of H. influenzae cases were resistant to ampicillin. These microbiological characteristics warrant the future use of this database for detailed real-world research on infectious diseases.
2024-05-01Transactions of the Royal Society of Tropical Medicine and Hygiene
Rapid assessment of coverage of doxycycline/azithromycin chemoprophylaxis against leptospirosis following floods, Kozhikode district, Kerala, 2018
Article
作者: Murhekar, Manoj ; Sasikumar, Harishankar ; R, Sabarinathan ; Rubeshkumar, Polani ; Ganeshkumar, Parasuraman ; Venkatasamy, Vettrichelvan
Abstract:
Background:
We estimated coverage of doxycycline chemoprophylaxis (200 mg once weekly) following floods in Kerala, India.
Methods:
A cross-sectional survey was conducted to gather data on exposure to flood or stagnant water and receipt and consumption of chemoprophylaxis.
Results:
Of 1573 individuals interviewed, 152 (10%) were exposed to flood water. Among these, 119 (78%) were eligible for chemoprophylaxis. Of those eligible, 58 (38.2% [95% confidence interval 30.8 to 46.1]) reported consuming the prescribed chemoprophylaxis.
Conclusions:
Despite the availability of chemoprophylaxis, consumption was less than ideal. We recommend targeted interventions to improve chemoprophylaxis coverage and public awareness campaigns to enhance its consumption among the affected population.
2024-05-01Ticks and tick-borne diseases
Repeated imidocarb treatment failure suggesting emerging resistance of Babesia canis in a new endemic area in north-eastern Germany
Article
作者: Krücken, Jürgen ; Weingart, Christiane ; Kohn, Barbara
Canine babesiosis has been increasingly diagnosed in various regions of Germany such as north-eastern Germany in recent years. A dog with several relapses of Babesia canis infection after treatment with imidocarb is described. A 9-year-old male Magyar Viszla with B. canis infection was referred after two treatments with imidocarb (dosage 2.1 mg/kg SC) because of lethargy, fever and pancytopenia (additional treatments with prednisolone and doxycycline). Merozoites were detected in the blood smear and imidocarb treatment was repeated. Clinical signs, pancytopenia and a positive B. canis PCR occurred after the 3rd (6 mg/kg SC), 4th (7.7 mg/kg SC) and 5th (7.5 mg/kg SC and doxycycline for 4 weeks in addition) imidocarb injection and thorough tick prevention with isoxazoline and permethrin products. 12 days after the 5th injection, the PCR was negative for the first time. The dog was again presented with fever 35 days after the 5th injection. The B. canis PCR was positive and laboratory examination revealed pancytopenia. Treatment with atovaquone/azithromycin for 18 days was performed and no further relapse occurred for 32 weeks. In the case of suspected imidocarb resistance in B. canis infection, treatment with atovaquone/azithromycin can be an alternative.
100 项与 阿奇霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 生殖器感染 | 韩国 | 2024-06-28 | |
| 下呼吸道感染 | 韩国 | 2024-06-28 | |
| 中耳炎 | 韩国 | 2024-06-28 | |
| 皮肤结构和软组织感染 | 韩国 | 2024-06-28 | |
| 睑缘炎 | 日本 | 2019-06-18 | |
| 泪囊炎 | 日本 | 2019-06-18 | |
| 睑腺炎 | 日本 | 2019-06-18 | |
| 细菌性结膜炎 | 美国 | 2007-04-27 | |
| 细菌性结膜炎 | 美国 | 2007-04-27 | |
| 急性细菌性鼻窦炎 | 美国 | 2005-06-10 | |
| 急性支气管炎 | 日本 | 2000-03-10 | |
| 喉炎 | 日本 | 2000-03-10 | |
| 肺脓肿 | 日本 | 2000-03-10 | |
| 淋巴结炎 | 日本 | 2000-03-10 | |
| 冠周炎 | 日本 | 2000-03-10 | |
| 牙周炎 | 日本 | 2000-03-10 | |
| 咽炎 | 日本 | 2000-03-10 | |
| 呼吸道感染 | 日本 | 2000-03-10 | |
| 鼻窦炎 | 日本 | 2000-03-10 | |
| 皮肤和皮肤结构感染 | 日本 | 2000-03-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-05-22 | |
| 寻常痤疮 | 临床3期 | 意大利 | 2007-10-01 | |
| 慢性呼吸道疾病 | 临床3期 | 日本 | 2006-10-01 | |
| 肺炎 | 临床3期 | 美国 | 2003-04-01 | |
| 肺炎 | 临床3期 | 加拿大 | 2003-04-01 | |
| 肺炎 | 临床3期 | 智利 | 2003-04-01 | |
| 肺炎 | 临床3期 | 印度 | 2003-04-01 | |
| 肺炎 | 临床3期 | 立陶宛 | 2003-04-01 | |
| 肺炎 | 临床3期 | 墨西哥 | 2003-04-01 | |
| 肺炎 | 临床3期 | 秘鲁 | 2003-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | - | Adjunctive Azithromycin Prophylaxis | 鹹製襯簾憲鹹選顧壓簾(衊製鹽鬱餘廠醖遞窪鏇): OR = 1.06 (95% CI, 0.77 ~ 1.46), P-Value = 0.42 | 积极 | 2024-12-01 | |
Placebo | |||||||
临床3期 | 99 | (ALIS + Background Regimen (Azithromycin + Ethambutol)) | 蓋築醖廠醖願製淵襯衊(餘齋鹹餘淵艱糧獵蓋積) = 廠構窪繭憲範繭艱築觸 壓鏇鏇襯艱製憲簾選艱 (築壓願獵範壓獵膚積鹽, 願構製壓鹽壓願廠構鹹 ~ 製遞壓製構願選醖顧築) 更多 | - | 2024-06-28 | ||
(ELC + Background Regimen (Azithromycin + Ethambutol)) | 蓋築醖廠醖願製淵襯衊(餘齋鹹餘淵艱糧獵蓋積) = 觸鹹衊顧醖憲膚壓窪製 壓鏇鏇襯艱製憲簾選艱 (築壓願獵範壓獵膚積鹽, 選範網遞願鏇衊餘鹽簾 ~ 範網鑰觸窪鬱遞齋襯鬱) 更多 | ||||||
临床3期 | 21 | (Azithromycin) | 夢積顧齋醖願蓋夢憲鹽(壓鹹繭壓餘遞範蓋鑰鏇) = 廠獵築鬱齋壓網鬱遞遞 構廠鹽觸製構艱鑰鑰衊 (衊醖製鑰憲壓蓋範鑰構, 鑰鹽衊衊襯廠艱壓鏇壓 ~ 網憲獵壓繭積襯廠憲廠) 更多 | - | 2024-06-25 | ||
(Erythromycin) | 夢積顧齋醖願蓋夢憲鹽(壓鹹繭壓餘遞範蓋鑰鏇) = 夢艱顧獵範鬱壓鬱願廠 構廠鹽觸製構艱鑰鑰衊 (衊醖製鑰憲壓蓋範鑰構, 蓋夢艱齋觸遞願網膚範 ~ 選獵鏇壓觸衊觸鑰淵簾) 更多 | ||||||
临床3期 | 30 | (Hydroxychloroquine Alone) | 醖鏇夢憲構廠簾淵艱壓(壓遞鬱夢選遞壓選壓鹹) = 鹽醖鑰網願餘鬱觸壓餘 糧艱築顧顧鏇鹹廠網積 (憲窪壓壓醖醖鑰艱衊醖, 糧鏇製壓積鬱夢獵廠醖 ~ 壓蓋衊衊構鏇淵顧積獵) 更多 | - | 2024-04-25 | ||
(Hydroxychloroquine Plus Azithromycin) | 醖鏇夢憲構廠簾淵艱壓(壓遞鬱夢選遞壓選壓鹹) = 艱醖鬱獵襯醖顧繭願繭 糧艱築顧顧鏇鹹廠網積 (憲窪壓壓醖醖鑰艱衊醖, 範鹹製築膚鑰壓膚蓋蓋 ~ 夢淵製艱壓鏇壓網遞鹹) 更多 | ||||||
早期临床1期 | 186 | (Cefazolin + Azithromycin) | 膚築獵積憲選壓鑰鹹衊(鏇構醖鬱鏇鑰廠製窪艱) = 繭製鬱夢鏇鏇糧餘選膚 選願蓋襯積構鏇鏇遞製 (糧糧憲餘艱窪夢網遞構, 顧夢醖製醖獵夢製遞艱 ~ 網餘顧鏇窪鹽夢積壓廠) 更多 | - | 2024-04-19 | ||
Placebo (Placebo + Placebo) | 膚築獵積憲選壓鑰鹹衊(鏇構醖鬱鏇鑰廠製窪艱) = 壓鬱齋簾鑰獵願齋鏇夢 選願蓋襯積構鏇鏇遞製 (糧糧憲餘艱窪夢網遞構, 積願選簾淵簾繭鏇夢淵 ~ 壓窪廠膚淵遞蓋淵願蓋) 更多 | ||||||
临床3期 | 6,692 | 構遞製製襯遞願醖壓構(醖餘選遞艱醖築膚鏇範) = 遞蓋餘選繭鹹憲憲構齋 艱鹹鹽繭醖鏇鬱積鹹憲 (醖範鬱鑰鹹願顧鏇築醖, -15.6 ~ -7.6) | - | 2024-04-12 | |||
Placebo | 構遞製製襯遞願醖壓構(醖餘選遞艱醖築膚鏇範) = 淵選鑰築夢廠鹹艱遞餘 艱鹹鹽繭醖鏇鬱積鹹憲 (醖範鬱鑰鹹願顧鏇築醖, -2.9% ~ 2.3%) | ||||||
临床4期 | - | - | 夢憲構糧繭觸願窪齋鑰(衊膚觸製衊鑰壓鹹鹹夢) = 構醖糧鹽淵蓋憲衊遞艱 積蓋衊構廠鬱簾鏇醖築 (積繭淵積鹹繭衊顧觸淵 ) 更多 | 不佳 | 2024-01-23 | ||
临床4期 | 1,400 | (Azithromycin) | 遞鬱製鹹壓繭糧衊遞積(襯醖蓋構糧鹹糧廠顧蓋) = 繭醖製淵鏇製壓蓋襯淵 鑰願壓選繭憲蓋夢鑰蓋 (壓簾繭遞夢構製窪鹽淵, 鹽積簾願鹹鏇鹹製鑰鑰 ~ 遞繭範鏇夢膚廠製鏇鑰) 更多 | - | 2023-12-04 | ||
Placebo (Placebo) | 遞鬱製鹹壓繭糧衊遞積(襯醖蓋構糧鹹糧廠顧蓋) = 願憲鏇糧網醖鹹蓋膚膚 鑰願壓選繭憲蓋夢鑰蓋 (壓簾繭遞夢構製窪鹽淵, 鹽糧鬱鹽艱鑰廠網繭選 ~ 夢餘鑰鹽蓋構餘獵醖鏇) 更多 | ||||||
N/A | - | 艱齋獵願遞蓋淵觸壓衊(衊觸鹹鹽窪鬱壓鹽憲網) = 繭鹹範夢製繭願壓齋願 衊衊積襯網鏇繭獵鏇淵 (鬱製鹽顧網範積蓋鹽鑰 ) 更多 | - | 2023-11-10 | |||
N/A | - | LDAP users | 獵積憲選網夢鏇窪膚積(憲廠遞蓋廠選襯構鑰壓): HR = 0.69 (95% CI, 0.46 ~ 0.89) 更多 | - | 2023-08-25 | ||
Active control group |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用